PSDV (Mcap $29 M) 3x Approved Drugs // 1x in Phase 3 // NDA filing in Jan =10 BAGGER

[Biotechmaster]

THIS LOW FLOAT ROCKET IS DEFINITELY THE CHEAPEST BIOTECH OUT THERE ..PLEASE DO YOUR OWN DD FOLKS..

This undiscovered low float Stock will hit $7++ before FDA approval in 1H 2013 .PSDV will move into double digits easily with FDA approval for Blockbuster candidate Iluven for DME .There is NO FDA approved drugs for DME (Diabetic Macular Edema) a Blockbuster Market . Iluven is approved in Europe and Market launch will start during 2013

Upon US approval of ILUVIEN, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.

DME is a potentially blinding disease that affects over one million people in the United States. Currently there are no FDA approved drugs for the treatment of DME.The U.S. market for DME is $1.5 billion to $4 billion.


Psivida (PSDV)

Market Cap: $29.5 M
Cash: $17.65 M
Price: $1.27

Shares Out: 23.3


Mega Pipeline



Revenue Expectations in 4 EU Countries where the Product is approved



Pfizer Deal Summary



Overview



Upcoming Milestones



Summary


....

Heavy Accumulation by Institutions in last few weeks . Pfizer is third largest shareholder in Psivida !



Buyers 12/2/12 (5,053,134) BIG BUYERS
Sellers 12/2/12 (588,820)

Top Institutional Holders

Allan Gray ...2.8M
Orbis Investment ...2.2M
Pfizer Inc ...1.9M
North Run ...960.0K
Palo Alto ...813.7K
Ashton (Paul) ...457.5K
Morgan Stanley ...274.2K
Dimensional Fund ...257.9K
The Pennsylvania ...133.4K
Janney ...131.4K

--------



Our proven proprietary technologies enable us to achieve highly focused, long-term delivery of therapeutics. We have developed three of the only four products approved by either the US or EU for the long-term, sustained-released delivery of drug to treat chronic eye disease.

Our most recently approved product, ILUVIEN